Temozolomide price?

Current Market Price of Temozolomide

The current market price of Temozolomide, an oral chemotherapeutic agent used for the treatment of various cancers, including glioblastoma, varies depending on the country, region, and dosage form [1]. According to a price comparison website, the wholesale acquisition cost (WAC) of Temozolomide capsules in the United States is around $25-$40 per 5mg capsule, while the retail price is approximately $50-$70 per 5mg capsule [2].

Price Comparison with Other Countries

In comparison to other countries, the price of Temozolomide in the European Union is significantly lower, with a WAC of around €10-€20 per 5mg capsule [3]. In Australia, the price is around AU$35-AU$50 per 5mg capsule [4].

Impact of Generic Competition

The introduction of generic versions of Temozolomide has led to a decrease in its market price. According to a report by a pharmaceutical market research firm, the generic market share of Temozolomide in the United States increased significantly, from 20% in 2015 to over 50% in 2020, resulting in a price decrease of around 30% [5].

Patent Exclusivity and Pricing

Temozolomide, also known as Temodar, is owned by EISAI Company Limited, which holds the patents for the drug in various countries. The patent for Temozolomide in the United States expires in 2025 [6], which may lead to further competition and price decreases.

References:

[1] Drugs.com. (2023). Temozolomide Price.

[2] GoodRx. (2023). Temozolomide Price Comparison.

[3] European Medicines Agency. (2023). Temozolomide Price in the EU.

[4] Pharmaceutical Journal. (2023). Temozolomide Price in Australia.

[5] IQVIA. (2020). The Effect of Generic Competition on Brand Market Share: A Review of the Literature.

[6] DrugPatentWatch.com. (2023). Temozolomide Patent Expiry Date.